PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 28, 2020The Lancet1,102 citationsOpen Access

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

ABAdrian Murray BruntJHJoanne HavilandDWDuncan Wheatley

Key Points

Key points are not available for this paper at this time.

Abstract

National Institute for Health Research Health Technology Assessment Programme.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Brunt et al. (2020) studied this question.

synapsesocial.com/papers/69dfedb3915fa04953615261https://doi.org/10.1016/s0140-6736(20)30932-6
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials2013 · 1,470 citations
  2. 2OC-0596: Hypo- vs normofractionated radiation of early breast cancer in the randomized DBCG HYPO trial2018 · 7 citations
  3. 3Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline2018 · 620 citations
  4. 4Statistical Analysis of Correlated Data Using Generalized Estimating Equations: An Orientation2003 · 2,218 citations
  5. 5Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial2016 · 229 citations